

RECEIVED

4/SUPPL
IDS
0270

JAN 10 2001

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Typed or Printed Name Wilhelm Albert Palmen Jr.

Signature

Date

November 17, 2000

**NON FEE
TRANSMITTAL**

Note: Effective October 1, 1998.
Patent fees are subject to annual revision.

Attorney Docket Number UCSF-085CIP

First Named Inventor Nadel et al.

Application Number 09/616,223

Filing Date July 14, 2000

Group Art Unit Unassigned

Examiner Name Unassigned

Title: "PREVENTING AIRWAY MUCUS BY ADMINISTRATION OF EGF-R
ANTAGONISTS"

Enclosed are the following documents:

- ◆ Supplemental Information Disclosure Statement (1 page)
- ◆ Supplemental PTO Form 1449 (1 page)
- ◆ Return Postcard

CLAIMS

No. of claims as filed or after amendment	Most claims previously paid	Extra claims	Fee from below	Fee Due
Total claims	- 20	=	x	=
Ind. claims	- 3	=	x	=
Multiple Dependent claims			x	=

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	80	202	40	Independent claims in excess of 3
104	270	204	135	Multiple dependent claim
109	80	209	40	Reissue independent claims over original patent
110	18	210	9	Reissue claims in excess of and over original patent

SUBMITTED BY

Complete (if applicable)

Typed or Printed Name Paula A. Borden, BOZICEVIC, FIELD & FRANCIS LLP

Reg. Number 42,344

Signature

Date


November 17, 2000

Deposit Account

50-0815

RECEIVED

JAN 10 2001



TECH CENTER 1600/2000

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date.			
Typed or Printed Name	Wilhelm Albert Palmen Jr.		
Signature		Date	November 17, 2000
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Address to: Assistant Commissioner for Patents Washington, D.C. 20231		Attorney Docket	UCSF-085CIP
		First Named Inventor	Nadel et al.
		Application Number	09/616,223
		Filing Date	July 14, 2000
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Title: "PREVENTING AIRWAY MUCUS BY ADMINISTRATION OF EGF-R ANTAGONISTS"	

Sir:

This is a Supplemental Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-1449 listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

All of the references identified herein were disclosed in parent application Serial No. 09/375,597 and, as such, copies thereof are not included pursuant to the provisions of 37 C.F.R. §1.98(d).

This Supplemental Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815 may be charged therefor.

Respectfully submitted,
 BOZICEVIC, FIELD & FRANCIS LLP

Date: November 17, 2000

By:
 Paula A. Borden
 Registration No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP
 200 Middlefield Road, Suite 200
 Menlo Park, CA 94025
 Telephone: (650) 327-3400
 Facsimile: (650) 327-3231